This finding is expected, and the lower incidence of hypoglycemia is confirmed with the use of a new generation long-acting insulin analog (insulin degludec/liraglutide) co-formulation versus other therapeutic regimens such as basal/plus or basal/bolus. The gene discussed is INS; the disease is Hypoglycemia.